



we make lives healthier together



Palm Court, M Block, 601/A1, Link Road, Malad (W), Mumbai – 400064.



Forward looking statment

In this Annual Report we have disclosed forward-looking information to enble investors to comprehend our prospects and take informed investment decisions. This report and other statements- written and oral- that we periodically make contain forward- looking statements that set out anticipated results based on the management's plans and assumptions. We have tried, wherever possible to identify such statements by using words such as anticipate', 'estimate', 'expects', 'projects', 'intends', 'plans', 'believes', and words of similar substance in connection with any discussion of future performance.

We cannot guarantee that these foward-looking statements will be realized, although we believe we have been prudent in assumptions. The achievement of results is subject to risks, uncertainities and estimates taken as assumptions. Should known or unknown risks or uncertainites materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from those anticipated, estimated or projected. Investors should bear this in mind as they consider forward looking statements. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

HIRAN ORGOCHEM LIMITED

Registered Office: Palm Court, M Block, 601/A1, Link Road, Malad (West), Mumbai - 400 064.

PROXY FORM

| I / We | of | |
|--|--|--------|
| 1 / VVE | | |
| ORGOCHEM LIMITED hereby appoint | of | |
| or failing him/her, of | as my/our F | Proxy |
| to attend and vote for me/us and on my/our behalf at the 24th Annua Saturday, the 27th day of September, 2008 at 11:00 A.M. and at any | l General Meeting of the Company to be he | eld on |
| Regd.Folio.No No. of Shares held | | |
| Client I.D. No DP. ID. No | | |
| Signed on this day of Signature of Shareholder | | |
| Note: The Proxy form duly completed and signed must be deposited at the 48 hours before the time for holding the Meeting. | Registered Office of the Company not less | then |
| | | |
| HIDAN ODCOCHEM | HOPL | _ |
| HIRAN ORGOCHEM | | |
| Registered Office: Palm Court, M Block, 601/ A1, Link Ro | ad, Maiad (West), Mumbai – 400 064. | |
| ATTENDANCE S | LIP | |
| I/We hereby record my/our presence at the Twenty Fourth Annual Sports Club', Link Road, Malad (West), Mumbai - 400 064 on Satur A.M. | | |
| NameAddress | | |
| Regd.Folio.NoNo. of Shares held | | |
| Client I.D. No DP. ID. No | | |
| Name of Proxy/Representative, if any | | |
| Signature of the Shareholder(s)/Proxy/Representative | | |
| Shareholder / Proxy attending the Meeting must fill-in this Attendar venue of the Meeting | nce Slip and hand it over at the entrance of | the |

Strengthning our team. Adopting a more

balanced approach. Redefining our goals. And

Renewing our commitment to give our



core.

CORPORATE INFORMATION

AUDITORS:

M/s. B. L. Dasharda & Associates (Chartered Accountants)

BANKERS:

State Bank of India

REGISTERED OFFICE:

Palm Court, M Block, 601/A1, Link Road, Malad (W), Mumbai - 400064. Tel: 022 - 40953000

Fax: 022 - 40953099

Email: info@hiranorgochem.com Website: www.hiranorgochem.com

REGISTRAR AND SHARE TRANS-FER AGENTS:

Bigshare Service Pvt. Ltd. E – 2, Ansa Industrial Estate, Sakivihar Road, Saki Naka, Andheri (E),

Mumbai - 400072.

Tel: 022 - 2847 3474, 2847 0652/53

Fax: 022 - 2847 5207

Email: bigshare@bom7.vsnl.net.in

Hiran Orgochem 41 2008 Annual Report

BOARD OF DIRECTORS:

(Chairman and Managing Director)

Mr. Kantilal. M. Hiran

(Whole time director)

Mr. M. Kailash Kumar

Mr. Vijay K. Hiran

(Director)

(Director)

(Director)

(Director)

Mr. H.N.Bafna

Mr. Mukeh Naik

Mr. Ashok Lunia



ADDITIONAL INFORMATION PURSUANT TO PART IV OF SCHEDULE VI TO THE COMPANIES ACT, 1956.

BALANCE SHEET ABSTRACT AND COMPANY'S GENERAL BUSINESS PROFILE:-

| l. | Registration Details | | | | | | | |
|------|--|---------------------|-----------------------|---------------|--|--|--|--|
| | Registration No. | 29596 | State Code | 11 | | | | |
| | Balance Sheet Date | 31.03.2008 | | | | | | |
| II. | Capital raised during the year (in Rupees) | | | | | | | |
| | Public Issue | NIL | Rights Issue | NIL | | | | |
| | Bonus Issue | NIL | Private Placement | NIL | | | | |
| III. | Position of Mobilisation & Deployment of Funds (in Rupees) | | | | | | | |
| | Total Liabilities | 2,016,227,754 | Total Assets | 2,016,227,754 | | | | |
| | SOURCES OF FUNDS | | | | | | | |
| | Paid-up-Capital | 105,006,000 | Reserves and Surplus | 769,552,068 | | | | |
| | Secured Loans | 544,861,826 | Unsecured Loans | 21,775,000 | | | | |
| | Deferred Tax Liability | 40,229,776 | | | | | | |
| | APPLICATION OF FUNDS | | | | | | | |
| | Net Fixed Assets | 382,179,849 | Investments | 8,879,310 | | | | |
| | Net Current Assets | 1,089,489,315 | Misc.Expenditure | 876,196 | | | | |
| | Accumulated Losses | NIL | | | | | | |
| IV. | V. PERFORMANCE OF COMPANY | | | | | | | |
| | Turnover (Net of Excise) | 12,117,307,275 | Total Expenditure | 1,167,533,437 | | | | |
| | Profit/Loss before Tax + | 49,773,838 | Profit/Loss After Tax | 38,825,887 | | | | |
| | (+for Profit,-for Loss) | | | | | | | |
| | Earning Per Share Rs | 3.70 | Dividend | 5% | | | | |
| | (Annualised) | | | | | | | |
| V. | Generic Name of Principal Product : | | | | | | | |
| | (a) Item Code No. | | 294190-3 | | | | | |
| | Product Description | | CIPROFLOXACIN | | | | | |
| | | | HYDROCHLORIDE - USP | | | | | |
| | (b) Item Code No. | | N.A. | | | | | |
| | Product Description | PROJECT DEVELOPMENT | | | | | | |

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

KANTILAL M. HIRAN CHAIRMAN & MANAGING DIRECTOR MUKESH NAIK DIRECTOR

H.N.BAFNA DIRECTOR

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2008

| | Rupees | 31.03.2008 Rupees | 31.3.2007 Rupees |
|----|--|----------------------|---------------------|
| ^ | Cook flow from an accepting a skiriking | | |
| Α. | 1 0 | 40.770.000 | 00 771 004 |
| | Net profit before tax | 49,773,838 | 26,771,904 |
| | Adjustment for : Depreciation | 18,326,523 | 16,233,859 |
| | Investment Income | (13,502,231) | (11,061,033) |
| | (Profit)/Loss on sale of Investments (Net) | 0 | (250,000) |
| | Miscellaneous Expenditure | 354,634 | 319,164 |
| | Unrealised Foreign Exchange | (11,115,473) | (4,094,310) |
| | (Profit)/Loss on sale of Fixed Assets(Net) | 92,790 | (550,842) |
| | Interest & Other finance charges | 68,010,608 | 46,351,904 |
| | Operating profit before working capital changes | 111,940,689 | 73,720,646 |
| | Adjustment for: Debtors (117,666,126) | | 23,734,963 |
| | Inventories (55,580,326) | | (192,172,682) |
| | Loans & Advances (73,374,389) | | (321,746,476) |
| | Trade payables 190,612,540 | (56,008,301) | 37,352,801 |
| | Cash generated from operations | 55,932,388 | (379,110,748) |
| | Fringe Beneift Tax Paid | (255,000) | (350,686) |
| | Taxes paid Net of Refund | (9,840,077) | (30,517,152) |
| | Net cash from operating activities (A) | 45,837,311 | (409,978,586) |
| 3. | Cash flow from investing activities | | X |
| | Purchase of Fixed Assets (Including Capital Work in Progress) | (78,297,890) | (58,560,834) |
| | Sale/Adjustment of Fixed Assets | 180,000 | 8,218,000 |
| | Sale of Investment(Net) | (1,056,549) | 7,635,339 |
| | Miscellaneous Expenditure | (177,346) | (786,000) |
| | Interest received | 13,502,231 | 11,061,033 |
| | Net cash used in investing activities (B) | (65,849,554) | (32,432,462) |
| Э. | Cash flow from Financing Activities | | - |
| | Proceeds from issue of Share Capital | 0 | 360,958,000 |
| | Forfeiture of ShareWarrants Application Money | 0 | 5,634,200 |
| | Proceeds from borrowings | 92,897,315 | 151,344,963 |
| | Dividend paid | (5,250,300) | (11,586,000) |
| | Interest & Other finance charges | (68,010,608) | (46,351,904) |
| | Tax on Proposed Dividend | (892,288) | (1,624,937) |
| | Net cash from financing activities (C) | | 458,374,322 |
| | Net increase/(decrease) in cash and cash equivalents (A + B + C) | (1,268,124) | 15,963,274 |
| _ | Cash and Cash equivalents (Opening Balance) | 45,864,342 | 29,901,068 |
| | Cash and Cash equivalents (Closing Balance) | 44,596,218 | 45,864,342 |

^{1.} The above cash flow statement has been prepared under the "indirect method" as set out in the Accounting Standard 3 on cash flow statement issued by the institute of Chartered Accountants Of India .

AS PER OUR REPORT OF EVEN DATE

B.L.DASHARDA & ASSOCIATES

CHARTERED ACCOUNTANTS

B.L.DASHARDA, Partner

M.NO. 13708

MUMBAI, DATED: 28th June, 2008

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

KANTILAL M. HIRAN CHAIRMAN & MANAGING DIRECTOR

MUKESH NAIK DIRECTOR


H.N.BAFNA DIRECTOR

Hiran Orgochem 39 2008 Annual Report

Financial Summary

| PARTICULARS | Mar-04 | Mar-05 | Mar-06 | Mar-07 | (Rs Mn) Mar-08 |
|--------------------------|--------|--------|---------|---------|-------------------|
| PAID UP CAPITAL | 42.39 | 62.24 | 77.24 | 105.01 | 105.01 |
| SALES | 387.50 | 612.66 | 1216.71 | 1154.13 | 1278.02 |
| LESS: EXCISE DUTY | 35.51 | 39.25 | 65.35 | 70.42 | 87.51 |
| NET SALES | 351.99 | 573.41 | 1151.36 | 1083.71 | 1190.5 |
| PBDIT | 33.20 | 52.26 | 249.93 | 89.36 | 136.11 |
| PBIT | 27.25 | 43.15 | 237.29 | 73.13 | 117.78 |
| PBT | 12.41 | 24.61 | 203.26 | 26.77 | 49.77 |
| PAT | 8.15 | 13.66 | 133.82 | 10.77 | 38.83 |
| EPS | 1.92 | 2.63 | 19.11 | 1.03 | 3.70 |
| PROFITABILITY RATIOS (%) | | | | | |
| PBDIT | 9.43 | 9.11 | 21.71 | 8.25 | 11.43 |
| PBIT | 7.74 | 7.53 | 20.61 | 6.75 | 9.89 |
| PBT | 3.53 | 4.29 | 17.65 | 2.47 | 4.18 |
| PAT | 2.32 | 2.38 | 11.62 | 0.99 | 3.26 |

Note: Previous year figures were regrouped/rearranged wherever necessary



Hiran Orgochem 04 2008 Annual Report

www.reportjunction.com

^{2.} Cash and Cash equivalent as at the end of 31st March 2008 include bank deposits of Rs. 392.23 Lacs with the maturity period of exceeding 3 months.

^{3.} Previous years figures have been regrouped wherever necessary.



NOTES ANNEXED TO AND FORMING PART OF THE ACCOUNTS FOR THE YEAR ENDED 31ST MARCH, 2008.

| Capital Expenditure Incurred | 601.80 | 442.21 | 0.00 | 0.00 | 601.80 | 522.67 |
|------------------------------|--------|--------|------|------|-----------|-----------|
| During The Year | | | | | | |
| Unallocated Cost | | | | | 36.95 | 45.31 |
| Depreciation | | | | | 172.17 | 148.49 |
| Unallocated Depreciation | | | | | 11.09 | 13.84 |
| Other Non Cash Expenditure | | | | | 3.55 | 3.19 |
| GEOGRAPHICAL SEGMENT | | | | | | |
| Revenue (Gross Sales) | | | | | | |
| Domestic sales | | | | | 9,193.40 | 9,556.52 |
| Export sales | | | | | 3,586.83 | 1,984.78 |
| | | | | | 12,780.23 | 11,541.30 |

- 15. Issue of Optionally Fully Convertible Warrants(OFCW) The company had issued 16,75,000 Optionally Fully Convertible Warrants (OFCWs), aggregating to Rs 217.75 lacs, representing 10% of the exercise price, convertible at the sole option of the holder thereof, any time on or after 1st April, 2007 but before the expiry of 18 months from the date of allotment thereof, into 1 fully paid up equity share of face value of Rs. 10/- at an exercise price (including premium) of Rs. 130/- per warrant, subject to certain conditions as prescribed in the letter of allotment of OFCW. None of the warrant holders have exercised the option of conversion as on the date of the balance sheet.
- 16. Excise duty shown under the head Manufacturing & Other Expenses represents the aggregate of excise duty borne by the company and the difference between excise duty on the opening and closing stock of finished goods.
- 17. Previous years figures have been regrouped and recast wherever necessary.

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS

Signature to Schedules 1 to 15

AS PER OUR REPORT OF EVEN DATE B.L.DASHARDA & ASSOCIATES CHARTERED ACCOUNTANTS

KANTILAL M. HIRAN

DIRECTOR

H.N.BAFNA DIRECTOR

B.L.DASHARDA, Partner M.NO. 13708 MUMBAI, DATED: 28th June, 2008

CHAIRMAN & MANAGING DIRECTOR